Evidence map›Paper›PMID 32543775›Full record

ArticleCancer medicine2020

miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

Madhumathy G Nair, Jyothi S Prabhu, Aruna Korlimarla, Savitha Rajarajan, Hari P S, Roma Kaul, Annie Alexander, Rohini Raghavan, Srinath B S, Sridhar T S

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  4. G2/M Checkpoint Modulation: Insights from miRNA Profiles in FAM and Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. miRNAs in Cancer (Review of Literature).International journal of molecular sciences · 2022
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Madhumathy G NairDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Jyothi S PrabhuDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Aruna KorlimarlaDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Savitha RajarajanDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Hari P SDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Roma KaulDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Annie AlexanderDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Rohini RaghavanDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.
Srinath B SSri Shankara Cancer Hospital and Research Centre, Bangalore, India.
Sridhar T SDivision of Molecular Medicine, St. John's Research Institute, Bangalore, India.ORCID 0000-0003-1789-7347
St. John's National Academy of Health Sciences · INHCG Cancer Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the established benefits of long-term endocrine therapy, women with hormone receptor-positive breast cancer remain at risk for late relapse. The basis of this is multi-factorial including genetic, epigenetic, and host factors. In this study we have explored the epigenetic regulation of estrogen receptor (ER)-dependent molecular and cellular phenotype by hsa-miR-18a-5p using well-established human ER-positive (ER+) breast cancer cell lines. miR-18a was overexpressed in MCF7 and ZR-75-1 and this led to an increase in the proliferative ability of the cells and concurrently resulted in decreased expression of luminal markers and higher expression of the basal marker, cytokeratin 14. The cells became more migratory with a significant repression of E-cadherin and activation of the Wnt noncanonical pathway. We observed an activation of the planar cell polarity (PCP) pathway with increased activation of JNK pathway and eventually change in actin dynamics. There was increased F-actin polymerization in cells with higher expression of miR-18a. Examination of miR-18a expression in a set of human ER+ breast cancer specimens showed a negative correlation between miR-18a and ESR1 transcripts as well as ER protein. Kaplan-Meier survival analysis of the cohort stratified by tumor hsa-miR-18a-5p levels produced significant differences in disease-free survival (log rank P < .05). This observation was independently validated in the METABRIC cohort. These data provide support for a role of hsa-miR-18a-5p in altering the proliferative and migratory behavior of ER+ cells and its potential utility as a prognostic marker in clinical ER+ breast cancers.

Indexed as

Wnt Signaling PathwayBreast NeoplasmsFemaleHumansMicroRNAsMiddle AgedPrognosisReceptors, EstrogenSurvival AnalysisMicroRNAsMIRN18A microRNA, humanReceptors, EstrogenER-positive breast cancermigrationmiR-18aPlanar cell polarity pathwayWnt pathway

Identifiers

PMID32543775
PMCPMC7402845
OpenAlexW3034749418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.